Home/Dyve Biosciences/Tatyana Beldock

TB

Tatyana Beldock

Board Member

Dyve Biosciences

Therapeutic Areas

Oncology Immunology Rheumatology

Dyve Biosciences Pipeline

Drug	Indication	Phase
DYV800	Solid Tumors (Oncology)	Phase 2
DYV700	Acute Gouty Arthritis	Phase 2
DMAX Platform	Broad (Immunologic & Oncologic Diseases)	Platform

Leadership Team at Dyve Biosciences

Chief Executive Officer, Board Member

Executive Chairman of the Board

Philippe Schaison

Camilla Simpson

View full Dyve Biosciences profile